FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the

## N BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Stacy Michelle					2. Issuer Name <b>and</b> Ticker or Trading Symbol Flex Pharma, Inc. [FLKS]						(Ch	elationship (eck all applic	cable) or	g Pers	10% Ow	ner
(Last) C/O FLE	(Fi X PHARM	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/25/2018								Officer (give title below)		Other (specify below)	
800 BOYLSTON STREET, 24TH FLOOR				4.	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)	N M	A	02199									X Form f	iled by More		rting Persor One Repor	
(City)	(Si	tate)	(Zip)													
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date			Transaction ate lonth/Day/Y	Execution Date,		Code (Ins	ansaction Disposed Of (D) (Instr. 3, 4 ode (Instr. 5)			Beneficia	s ally following	Form: (D) or	orm: Direct ) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3	ion(s)			iiisu. 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$0.82	07/25/2018		A		10,000		(1)	07/25/2028	Common Stock	10,000	\$0	10,000		D	

## **Explanation of Responses:**

1. The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018.

## Remarks:

/s/ John McCabe, Attorney-in-07/26/2018 **Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.